Daily vitamin C tied to fewer harms and better survival in early blood cancer trial
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
The phase 2 EVITA randomized trial gave patients with precancerous or early blood cancers 1,000 mg oral vitamin C daily for one year or placebo. Vitamin C recipients had fewer adverse events and cytokine shifts linked to better outcomes; abnormal cell expansion did not differ significantly, but exploratory analysis found they were significantly more likely to be alive after follow-up. Results appear in the journal CANCER from the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team.
Continue in the app — vote & join in ➔Source: ScienceDaily · via ahirlevel.hu